Fundraising Fox
/Companies
Sign in

AltaThera Pharmaceuticals

Chicago, US · Delaware LLC

Find your way into AltaThera Pharmaceuticals

533 people in our graph share verified history with the AltaThera Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

John McKearnunlockedknows Stephen O'Sullivan · together at Searle (overlapped)
×2knows the team · via Pharmacia Corporation
knows the team · via Searle
knows the team · via Mallinckrodt
×6knows the team · via William Blair
knows the team · via City of Hope

AltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.

BiotechHealthtechMedical Devices

Founders & leadership

MB
Merrill BardenExecutive
SOStephen O'Sullivan
Stephen O'SullivanGeneral Counsel, Chief Compliance Officer, DirectorStephen O'Sullivan is General Counsel at AltaThera Pharmaceuticals, bringing decades of experience in legal and business management across the pharmaceutical and public sectors. He previously served as Assistant General Counsel at Pfizer, Senior Vice President and General Counsel at Pharmacia, Head of Litigation at Searle, and Chief of the Trial Division of the Cook County Public Defender's Office, where he oversaw 425 attorneys and handled complex litigation including capital cases.
JW
James WittenbergVice Presidentformer
BKBrandon Kashfian
Brandon KashfianFounder & Chief Business OfficerBrandon Kashfian is founder of AltaThera Pharmaceuticals and has held roles spanning clinical development, intellectual property, commercial operations, and product licensing in the pharmaceutical industry. He holds an A.B. in Sociology from Colby College, an M.D. from the University of Chicago Pritzker School of Medicine, an M.B.A. from the University of Chicago Booth School of Business, and an M.S. in Neurobiology & Physiology from Northwestern University.
JEJohn Ellis II
John Ellis IIJohn Ellis II is a healthcare executive with experience in pharmaceuticals, biologics, and medical devices across multiple therapeutic areas including cardiology, critical care, and oncology. He has a background in business development, including identifying and integrating acquisitions and licensing agreements.
MG
Maria GrayMA, RN, EdD
JP
Jim PerryMD

Board

JF
John FlavinBoard director
AS
Adam StrickbergerMD, FACC

Reported raises · per SEC filings

Form D private placements

$7.6M disclosed across 6 rounds · 2014–2019

▶$1.5MraisedAug 2019 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Brandon KashfianExecutive Officer
  • Jodi DevlinExecutive Officer
  • Stephen OsullivanExecutive Officer
Offering amount
$4M
Amount sold
$1.5M
Sales commissions
$29.6K
Placement agents
Silverwood Partners
First sale
Apr 2019
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedDec 2016 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen O?SullivanExecutive Officer, Director
  • James WittenbergExecutive Officer
  • Merrill BardenExecutive Officer
Offering amount
$3.5M
Amount sold
$3.4M
Minimum investment
$25K
First sale
Dec 2016
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$225KraisedNov 2016 · 4 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Brandon KashfianExecutive Officer, Director
  • Merrill BardenExecutive Officer
  • John SombergExecutive Officer
  • James WittenbergExecutive Officer
  • Rick WhiteExecutive Officer
  • Jay WelshExecutive Officer
  • Stephen O'SullivanExecutive Officer, Director
Offering amount
$1M
Amount sold
$225K
Sales commissions
$80K
Placement agents
M Barc Investment Group, Inc.
First sale
Oct 2016
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1MraisedJul 2015 · 1 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Stephen O'SullivanExecutive Officer, Director
  • Mahlaqa PatelExecutive Officer
  • James WittenbergExecutive Officer
  • John FlavinDirector
  • Brandon KashfianExecutive Officer, Director
  • Merrill BardinExecutive Officer
  • Jay WelshExecutive Officer
Offering amount
$1M
Amount sold
$1M
Minimum investment
$1M
Sales commissions
$80K
Placement agents
M Barc Investment Group, Inc.
First sale
Jul 2015
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1MraisedFeb 2015 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen O'SullivanExecutive Officer
  • Brandon KashfianExecutive Officer
  • John FlavinDirector
  • Merrill BardenExecutive Officer
  • James WittenbergExecutive Officer
Offering amount
$1M
Amount sold
$1M
Minimum investment
$1M
Sales commissions
$80K
Placement agents
M Barc Investment Group, Inc.
First sale
Oct 2014
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedJan 2015 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Merrill BardenExecutive Officer
  • Stephen O'SullivanExecutive Officer
  • James WittenbergExecutive Officer
  • John FlavinDirector
  • Brandon KashfianExecutive Officer
Offering amount
$500K
Amount sold
$500K
Minimum investment
$500K
Sales commissions
$40K
Placement agents
M Barc Investment Group, Inc.
First sale
Mar 2014
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does AltaThera Pharmaceuticals do?
AltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
How much funding has AltaThera Pharmaceuticals raised?
AltaThera Pharmaceuticals has disclosed $7.6M raised across 6 rounds.
Where is AltaThera Pharmaceuticals headquartered?
AltaThera Pharmaceuticals is headquartered in Chicago, US.